Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

被引：3

作者：

Robinson, Troy ^{[1
,2
]}

Bowman, Robert L. ^{[2
,3
]}

Persaud, Sonali ^{[2
]}

Liu, Ying ^{[4
,5
]}

Gao, Qi ^{[6
]}

Zhang, Jing-Ping ^{[7
]}

Sun, Xiaotian ^{[6
]}

Sciambi, Adam ^{[8
]}

Llanso, Aaron ^{[9
]}

Famulare, Christopher ^{[10
]}

Goldberg, Aaron D. ^{[11
]}

Dogan, Ahmet ^{[6
]}

Roshal, Mikhail ^{[6
]}

Levine, Ross L. ^{[2
,10
,11
,12
]}

Xiao, Wenbin ^{[2
,6
,10
]}

机构：

[1] Gerstner Sloan Kettering Grad Sch Biomed Sci, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Ctr Epigenet Res, New York, NY 10021 USA

[4] Mem Sloan Kettering, Hematopathol Serv, Dept Pathol & Lab Med, New York, NY USA

[5] Mem Sloan Kettering, Mol Diagnost Serv, Dept Pathol & Lab Med, New York, NY USA

[6] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Hematopathol Serv, New York, NY USA

[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, New York, NY 10021 USA

[8] Mission Bio Inc, San Francisco, CA USA

[9] Mission Bio, San Francisco, CA USA

[10] Mem Sloan Kettering Canc Ctr, Ctr Hematol Malignancies, New York, NY 10021 USA

[11] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA

[12] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166501

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2275 / 2277

页数：3

共 50 条

[41] Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia
Palmieri, Raffaele
Buccisano, Francesco
Maurillo, Luca
Del Principe, Maria, I
Paterno, Giovangiacinto
Venditti, Adriano
Martinelli, Giovanni
Cerchione, Claudio
MINERVA MEDICA, 2020, 111 (05) : 386 - 394
[42] Reproducibility of measurable residual disease detection by flow cytometry in acute myeloid leukemia
Roehnert, M. A.
Kramer, M.
Schadt, J.
Ensel, P.
Thiede, C.
Krause, S.
Buecklein, V
Hoffmann, J.
Jaramillo, S.
Schlenk, R.
Roellig, C.
Bornhaeuser, M.
McCarthy, N.
Freeman, S.
Oelschlaegel, U.
von Bonin, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 278 - 278
[43] Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Gang, Margery
Othus, Megan
Walter, Roland B.
CELLS, 2025, 14 (04)
[44] Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia
Wen, Zhihao
Xue, Xinran
Li, Shuhua
Liu, Yu
Jin, Yongmei
Jiang, Nenggang
Liao, Hongyan
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2025, 149 (03) : 262 - 270
[45] Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions
Moritz, Jennifer
Schwab, Antonia
Reinisch, Andreas
Zebisch, Armin
Sill, Heinz
Woelfler, Albert
BIOMEDICINES, 2024, 12 (03)
[46] Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
Roehnert, Maximilian A.
Kramer, Michael
Schadt, Jonas
Ensel, Philipp
Thiede, Christian
Krause, Stefan W.
Buecklein, Veit
Hoffmann, Joerg
Jaramillo, Sonia
Schlenk, Richard F.
Roellig, Christoph
Bornhaeuser, Martin
McCarthy, Nicholas
Freeman, Sylvie
Oelschlaegel, Uta
von Bonin, Malte
LEUKEMIA, 2022, 36 (09) : 2208 - 2217
[47] Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study
Scott, Stuart
Dillon, Richard
Thiede, Christian
Sadiq, Sadia
Cartwright, Ashley
Clouston, Hazel J.
Travis, Debbie
Mokretar, Katya
Potter, Nicola
Chantry, Andrew
Whitby, Liam
BLOOD ADVANCES, 2023, 7 (14) : 3686 - 3694
[48] Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia
Maiti, Abhishek
DiNardo, Courtney D.
Wang, Sa A.
Jorgensen, Jeffrey L.
Kadia, Tapan M.
Daver, Naval
Short, Nicholas J.
Yilmaz, Musa
Pemmaraju, Naveen
Borthakur, Gautam
Bose, Prithviraj
Issa, Ghayas C.
Ferrajoli, Alessandra
Jabbour, Elias
Jain, Nitin
Garcia-Manero, Guillermo
Ohanian, Maro
Takahashi, Koichi
Montalban-Bravo, Guillermo
Masarova, Lucia
Burger, Jan A.
Thompson, Philip A.
Verstovsek, Srdan
Sasaki, Koji
Andreeff, Michael
Rausch, Caitlin R.
Montalbano, Kathryn
Pierce, Sherry A.
Kantarjian, Hagop M.
Konopleva, Marina
Ravandi, Farhad
BLOOD, 2020, 136
[49] Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.
Pratz, Keith
Jonas, Brian Andrew
Pullarkat, Vinod
Recher, Christian
Schuh, Andre C.
Thirman, Michael J.
Garcia, Jacqueline Suen
Dinardo, Courtney Denton
Vorobyev, Vladimir
Fracchiolla, Nicola
Yeh, Su-Peng
Jang, Jun Ho
Ozcan, Muhit
Yamamoto, Kazuhito
Illes, Arpad
Zhou, Ying
Dail, Monique
Chyla, Brenda
Potluri, Jalaja
Dohner, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
Maiti, Abhishek
DiNardo, Courtney D.
Wang, Sa A.
Jorgensen, Jeffrey
Kadia, Tapan M.
Daver, Naval G.
Short, Nicholas J.
Yilmaz, Musa
Pemmaraju, Naveen
Borthakur, Gautam
Bose, Prithviraj
Issa, Ghayas C.
Ferrajoli, Alessandra
Jabbour, Elias J.
Jain, Nitin
Garcia-Manero, Guillermo
Ohanian, Maro
Takahashi, Koichi
Montalban-Bravo, Guillermo
Masarova, Lucia
Burger, Jan A.
Thompson, Philip A.
Verstovsek, Srdan
Sasaki, Koji
Andreeff, Michael
Rausch, Caitlin R.
Montalbano, Kathryn S.
Pierce, Sherry
Qiao, Wei
Ning, Jing
Kantarjian, Hagop M.
Konopleva, Marina Y.
Ravandi, Farhad
BLOOD ADVANCES, 2021, 5 (07) : 1876 - 1883

← 1 2 3 4 5 →